Sudha Sundar is a gynaecological cancer surgeon and a clinical academic. Her research programme focusses on improving cancer diagnostics, cancer surgery and addressing inequalities in cancer outcomes. Sudha’s research has led to change of NICE guidance to recommend maximum cytoreduction surgery for ovarian cancer. She has recently completed her term as the President of the British Gynaecological Cancer Society (2019-2022), the first women gynaecological oncologist to be elected to this post. 

She is now National Ovarian Cancer audit surgical lead (2023 – to date) and is spearheading the innovative use of routinely collected data to drive outcomes for women with ovarian cancer.    She has co-chaired the International Gynaecological cancer society conference Scientific program committee in 2024 and is on the International advisory board of Lancet Oncology (2025-)

She has co-chaired the International Gynaecological cancer society conference Scientific program committee in 2024 and is on the International advisory board of Lancet Oncology (2025-)